Literature DB >> 11596160

Early pulmonary infection, inflammation, and clinical outcomes in infants with cystic fibrosis.

M Rosenfeld1, R L Gibson, S McNamara, J Emerson, J L Burns, R Castile, P Hiatt, K McCoy, C B Wilson, A Inglis, A Smith, T R Martin, B W Ramsey.   

Abstract

A thorough understanding of the early natural history of cystic fibrosis (CF) lung disease is critical for the development of effective interventions in the youngest patients. We assessed the evolution of pulmonary infection, inflammation, and clinical course among 40 infants over a 2-year period through annual bronchoalveolar lavage (BAL) for culture and measurements of pro- and anti-inflammatory cytokines, semiannual infant pulmonary function testing, and quarterly clinical evaluations. Both the prevalence of CF pathogens and their density in BAL fluid increased with age. Infants had neutrophilic lower airway inflammation and elevated IL-8 concentrations independent of whether CF pathogens were recovered. Total leukocyte and neutrophil densities and IL-8 concentrations increased with density of CF pathogens in BAL fluid, whether the isolated organism was P. aeruginosa or another pathogen. IL-10 concentrations were similar in CF subjects and non-CF historical controls. Infants generally had suboptimal growth (low weight and height percentiles) and obstructive lung disease (decreased expiratory flows and air trapping). Subjects from whom CF pathogens were isolated at > 10(5) cfu/mL had the worst air trapping and lowest Brasfield chest X-ray scores. Our findings provide a foundation for future studies of early intervention in CF lung disease, including antimicrobial and anti-inflammatory therapy. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11596160     DOI: 10.1002/ppul.1144

Source DB:  PubMed          Journal:  Pediatr Pulmonol        ISSN: 1099-0496


  114 in total

1.  Exaggerated inflammatory responses mediated by Burkholderia cenocepacia in human macrophages derived from Cystic fibrosis patients.

Authors:  Benjamin T Kopp; Basant A Abdulrahman; Arwa A Khweek; Surender B Kumar; Anwari Akhter; Richard Montione; Mia F Tazi; Kyle Caution; Karen McCoy; Amal O Amer
Journal:  Biochem Biophys Res Commun       Date:  2012-06-20       Impact factor: 3.575

2.  Binding of Pseudomonas aeruginosa AlgZ to sites upstream of the algZ promoter leads to repression of transcription.

Authors:  Deborah M Ramsey; Patricia J Baynham; Daniel J Wozniak
Journal:  J Bacteriol       Date:  2005-07       Impact factor: 3.490

Review 3.  New insights into pulmonary inflammation in cystic fibrosis.

Authors:  S Rao; J Grigg
Journal:  Arch Dis Child       Date:  2006-09       Impact factor: 3.791

4.  Use of phage display to identify potential Pseudomonas aeruginosa gene products relevant to early cystic fibrosis airway infections.

Authors:  Christiane Beckmann; Mitchell Brittnacher; Robert Ernst; Nicole Mayer-Hamblett; Samuel I Miller; Jane L Burns
Journal:  Infect Immun       Date:  2005-01       Impact factor: 3.441

5.  Inhibition of high-mobility group box 1 protein (HMGB1) enhances bacterial clearance and protects against Pseudomonas Aeruginosa pneumonia in cystic fibrosis.

Authors:  Maria Entezari; Daniel J Weiss; Ravikumar Sitapara; Laurie Whittaker; Matthew J Wargo; JianHua Li; Haichao Wang; Huan Yang; Lokesh Sharma; Binh D Phan; Mohammad Javdan; Sangeeta S Chavan; Edmund J Miller; Kevin J Tracey; Lin L Mantell
Journal:  Mol Med       Date:  2012-05-09       Impact factor: 6.354

Review 6.  Mapping targetable inflammation and outcomes with cystic fibrosis biomarkers.

Authors:  Olivia Giddings; Charles R Esther
Journal:  Pediatr Pulmonol       Date:  2017-07-17

7.  Unique lipid a modifications in Pseudomonas aeruginosa isolated from the airways of patients with cystic fibrosis.

Authors:  Robert K Ernst; Samuel M Moskowitz; Julia C Emerson; Gretchen M Kraig; Kristin N Adams; Megan D Harvey; Bonnie Ramsey; David P Speert; Jane L Burns; Samuel I Miller
Journal:  J Infect Dis       Date:  2007-08-22       Impact factor: 5.226

Review 8.  Nontuberculous mycobacteria: the changing epidemiology and treatment challenges in cystic fibrosis.

Authors:  Janice M Leung; Kenneth N Olivier
Journal:  Curr Opin Pulm Med       Date:  2013-11       Impact factor: 3.155

Review 9.  Cystic fibrosis: exploiting its genetic basis in the hunt for new therapies.

Authors:  James L Kreindler
Journal:  Pharmacol Ther       Date:  2009-11-10       Impact factor: 12.310

10.  A neutrophil intrinsic impairment affecting Rab27a and degranulation in cystic fibrosis is corrected by CFTR potentiator therapy.

Authors:  Kerstin Pohl; Elaine Hayes; Joanne Keenan; Michael Henry; Paula Meleady; Kevin Molloy; Bakr Jundi; David A Bergin; Cormac McCarthy; Oliver J McElvaney; Michelle M White; Martin Clynes; Emer P Reeves; Noel G McElvaney
Journal:  Blood       Date:  2014-06-16       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.